Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sepracor introduces Alvesco inhalation aerosol in US
Alvesco HFA is a new inhaled corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. This
Alvesco HFA is a new inhaled corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. This
Dr Bacopoulos’s previous leadership roles include CEO and president of Aton Pharma, where he led the development of Zolinza, approved for the treatment of cutaneous T-cell lymphoma. Dr
The basis for termination is Shaklee’s uncured, notified breaches of the license agreement arising from its failure to pay amounts to NIR Diagnostics when due. As previously announced,
This payment is a result of the submission of an investigational new drug application by Pfizer for the clinical development of an antibody generated by Medarex’s UltiMAb technology.
Synthon believes that it has a first to file abbreviated new drug application (ANDA) application for the generic that can entitle it to 180 days of generic exclusivity
Dr Landes will be responsible for directing the discovery and preclinical development of therapeutic antibodies at Takeda’s antibody IND engine and center of excellence for biologics. Dr Landes
In preclinical studies in rats and dogs, LT-NS001 was shown to cause significantly less damage to the gastrointestinal tract than equivalent doses of naproxen. The study will assess
The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes. Anu Acharya, CEO of Ocimum
Mr Amat will oversee the financial and information technology departments of the company. Most recently, Mr Amat has served as the CFO of Sodexho, a publicly traded food
This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of Reolysin given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include